Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$50.89 USD

50.89
49,137,042

-3.07 (-5.69%)

Updated Sep 16, 2025 03:59 PM ET

After-Market: $50.35 -0.54 (-1.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (75 out of 245)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Debanjana Dey headshot

Hims & Hers Expands AI and Technology Focus to Advance Digital Care

by Debanjana Dey

HIMS boosts AI investment and appoints a new CTO as it advances personalized, technology-driven digital healthcare at scale.

Zacks Equity Research

Company News for Sep 16, 2025

by Zacks Equity Research

Companies in The News Are: NVDA,HIMS,MSFT,NFLX

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $54.03, signifying a -2.65% move from its prior day's close.

Zacks Equity Research

OMCL or HIMS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Zacks Equity Research

Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know

by Zacks Equity Research

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Debanjana Dey headshot

Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

by Debanjana Dey

HIMS accelerates with new men's health launches, global expansion plans and strong subscriber-driven growth, but rising costs strain gross margins.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $47.79, marking a -3.73% move from the previous day.

Debanjana Dey headshot

Hims & Hers Expanding Partnerships to Build a Global Health Ecosystem

by Debanjana Dey

HIMS expands its digital health footprint with global moves, top-tier partnerships and more than 1,500 providers.

Zacks Equity Research

Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock

by Zacks Equity Research

Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Debanjana Dey headshot

HIMS' Personalized Wellness Platform Expands Preventive Care Access

by Debanjana Dey

Hims & Hers expands its personalized wellness platform, aiming to reshape preventive care through tech-driven, holistic solutions.

Debanjana Dey headshot

HIMS vs. AMWL: Which Stock Has the Stronger Global Growth Strategy?

by Debanjana Dey

Hims & Hers expands globally, while Amwell leans on federal contracts and software growth. Let's see which has the edge in earnings growth & strategic expansion.

Debanjana Dey headshot

Hims & Hers Scales Growth Through Subscriptions and Care Expansion

by Debanjana Dey

HIMS fuels growth through subscriptions, expanding care offerings and building proprietary health infrastructure at scale.

Zacks Equity Research

Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Debanjana Dey headshot

Hims & Hers Fuels Growth via Market Expansion and New Care Verticals

by Debanjana Dey

HIMS eyes long-term growth with new hormonal health offerings, international expansion and high GLP-1 retention.

Zacks Equity Research

Zacks Investment Ideas feature highlights: IonQ, Hims and Hers, Eli Lilly and TransMedics

by Zacks Equity Research

Insider moves in IonQ, Hims and Hers, Eli Lilly, and TransMedics reveal bold buys, record sales, and signals worth watching.

Andrew Rocco headshot

3 Unusual Insider Transactions you Should Know About

by Andrew Rocco

While no single indicator can guarantee a stock's performance, the pattern of insider transactions can provide a powerful glimpse into a company's prospects.

Debanjana Dey headshot

Hims & Hers Stock Plunges 21.3% in 3 Months: Time to Hold or Exit?

by Debanjana Dey

HIMS records subscriber surge and revenue growth in second-quarter 2025, but rising costs strain gross margins.

Debanjana Dey headshot

Hims & Hers Drives the Consumer-Centric Transformation in Digital Care

by Debanjana Dey

HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.

Zacks Equity Research

Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Debanjana Dey headshot

Hims & Hers Redefines Virtual Care With Integrated Tech Platforms

by Debanjana Dey

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

Zacks Equity Research

HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down

by Zacks Equity Research

Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.

Mark Vickery headshot

Selloff? What Selloff? Monday Market Rebound

by Mark Vickery

Palantir is way up after reporting Q2 results Monday afternoon, while HIMS and VRTX are way off highs.

Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Hims & Hers Health (HIMS) delivered earnings and revenue surprises of -5.56% and -1.51%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.

Zacks Equity Research

Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +130.43% and +7.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?